Literature DB >> 18829273

[Antiepileptic drugs in pediatric migraine].

J-C Cuvellier1, A Riquet, L Vallée.   

Abstract

According to the criteria of the International Headache Society, migraine occurs in approximately 5 to 10% of children. As many as 30% of young patients with migraine experience such frequent and disabling attacks, or have unsatisfactory results and/or experience adverse effects with pharmacologic treatment of acute migraine attack, that daily preventive medications are required. Many studies have investigated the use of antiepileptic drugs in this indication but there is a paucity of placebo-controlled studies. So far, in the setting of migraine with and without aura, only flunarizine and topiramate have proved their efficacy in more than one placebo-controlled study. Uncontrolled studies suggest the possible efficacy of valproic acid, gabapentin, levetiracetam, zonisamide, and magnesium in preventive therapy of childhood periodic syndromes. Most of antiepileptic drugs used in pediatric preventive therapy are well tolerated. The most common adverse events are asthenia and somnolence.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18829273     DOI: 10.1016/j.arcped.2008.07.020

Source DB:  PubMed          Journal:  Arch Pediatr        ISSN: 0929-693X            Impact factor:   1.180


  3 in total

Review 1.  Migraine treatment in developmental age: guidelines update.

Authors:  Laura Papetti; Alberto Spalice; Francesco Nicita; Maria Chiara Paolino; Rosa Castaldo; Paola Iannetti; Maria Pia Villa; Pasquale Parisi
Journal:  J Headache Pain       Date:  2010-03-27       Impact factor: 7.277

2.  A randomized trial of propranolol versus sodium valproate for the prophylaxis of migraine in pediatric patients.

Authors:  Elham Bidabadi; Mehryar Mashouf
Journal:  Paediatr Drugs       Date:  2010-08-01       Impact factor: 3.022

3.  Comparing Zonisamide With Sodium Valproate in the Management of Migraine Headaches: Double-Blind Randomized Clinical Trial of Efficacy and Safety.

Authors:  Farhad Assarzadegan; Hanif Tabesh; Seyed-Mostafa Hosseini-Zijoud; Andrew David Beale; Arya Shoghli; Mahmood Ghafoori Yazdi; Behnam Mansouri; Omid Hesami; Nahid Beladi Moghadam; Hosein Delavar Kasmaei
Journal:  Iran Red Crescent Med J       Date:  2016-04-30       Impact factor: 0.611

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.